Nigeria: A Case for Investments in Pharmaceutical Manufacturing in Nigeria

[Vanguard] Nigeria is home to over 200 million people who are susceptible to a set of health problems that are linked and interact synergistically, contributing to its excess burden of disease: which includes the rising rates of non-communicable diseases, endemic diseases, and emerging and re-emerging infections. If Nigeria is to reduce its disease burden and forge a path towards sustainable economic development, it must invest heavily in science and innovation - investing and strengthening pharmaceutical

Original URL: Click here to visit original article